Non Hodgkin Lymphoma (NHL) Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Non Hodgkin Lymphoma (NHL) Market Size By 2025?
The market for non-hodgkin lymphoma (NHL) has seen significant growth in recent times. An increase from $10.11 billion in 2024 to $10.86 billion in 2025 is projected, which represents a compound annual growth rate (CAGR) of 7.5%. The historical growth is a result of factors such as the rising occurrence of NHL, cutting-edge advancements in diagnostic techniques, chemotherapy and immunotherapy, more investment in clinical research and drug development, as well as enhanced survival rates.

How Big Is the Non Hodgkin Lymphoma (NHL) Market Size Expected to Grow by 2029?
The market for non hodgkin lymphoma (NHL) is predicted to witness significant expansion in the upcoming years, with estimates pointing to a value of $15 billion by 2029, made possible by an 8.4% compound annual growth rate (CAGR). This surge in growth during the forecast period can be credited to an increasing aging population, advances in targeted treatments, groundbreaking immunotherapy technologies, precision medicine methodologies, and a rise in awareness and early diagnoses. The future also points towards the emergence of biosimilars as a major trend, along with the integration of next-generation sequencing, adoption of car-t cell therapies, groundbreaking chemotherapy drugs, and the application of real-world evidence and outcomes research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Key Market Drivers Powering Non Hodgkin Lymphoma (NHL) Market Expansion and Growth?
The rise in non-Hodgkin lymphoma prevalence is anticipated to drive the expansion of the non-Hodgkin lymphoma market. This form of cancer originates in the lymphatic system, a key part of the immune system. The rate of non-Hodgkin lymphoma captures the number of people in a population presently diagnosed with or living with this particular disease at a given moment. The treatment for non-Hodgkin lymphoma is designed to improve patient outcomes by precisely managing and targeting the cancer cells. For example, in January 2023, the American Cancer Society, a health organization focused on cancer in the US, shared that non-Hodgkin lymphoma accounted for 4% of all cancers and projected that around 80,550 Americans, 44,880 men and 35,670 women, would be impacted by this disease in 2023. It also predicted that around 20,180 people would succumb to non-Hodgkin lymphoma in the same year. Additionally, in May 2022, according to the Canadian Cancer Society, a cancer charity located in Canada, an estimated 11,400 Canadians would be diagnosed with non-Hodgkin lymphoma in the year 2022, with the disease expected to claim about 3,000 lives. Hence, the rising prevalence of non-Hodgkin lymphoma significantly contributes to the growth of the non-Hodgkin lymphoma market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What Long-Term Trends Will Define the Future of the Non Hodgkin Lymphoma (NHL) Market?
Drug innovation advancements have emerged as a major trend impacting the non-Hodgkin lymphoma market. Businesses in this sector are striving to develop new products to maintain their market presence. For example, in December 2022, Genentech Inc., a biotechnology firm based in the USA, got FDA approval for Lunsumio. This novel bispecific antibody, designed for the treatment of relapsed or refractory follicular lymphoma, represents a new form of fixed-duration cancer treatment immunotherapy. As a readily available treatment option, there's no need for patients to await for this immunotherapy treatment. The FDA greenlighted the product following encouraging findings from the Lunsumio Phase II GO29781 study conducted on individuals with extensively treated FL, especially those at a higher risk of disease progression or resistant to previous treatments.

What Are the Emerging Segments in the Non Hodgkin Lymphoma (NHL) Market?
The non hodgkin lymphoma (nhl) market covered in this report is segmented -

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma
2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Who Are the Global Leaders in the Non Hodgkin Lymphoma (NHL) Market?
Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Which are the Top Profitable Regional Markets for the Non Hodgkin Lymphoma (NHL) Industry?
North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10676

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.